The move comes as patients continue to struggle with access to popular, brand-name weight loss medications such as Wegovy and Zepbound, which have been in short supply for much of the year.
Liraglutide, sold under brand name Saxenda by Novo Nordisk, has seen its patents expire. Hims & Hers has secured a core supplier for its generic version of liraglutide and has said it plans to offer it as a more affordable option to its branded counterparts.
The FDA recently reported that the shortage of Eli Lilly’s Zepbound has resolved, though Novo Nordisk’s Wegovy and Ozempic — which the agency approved as a diabetes medication but sometimes is prescribed off-label for weight loss — still are considered in short supply.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.